Effect of Narrative Education on Glycemic Control in Adults With Type 2 Diabetes in Primary Care
Condition(s) studied
Investigational drug(s) / intervention(s)
Structured Narrative Education Program: Two individual face-to-face narrative sessions (20-30 minutes) at Day 0 and Day 15 plus four brief reinforcement phone calls (3-5 minutes) at Days 30, 45, 60, and 75 to support diabetes self-care goal setting and adherence.
Study summary
Type 2 diabetes is common in primary care, and daily self-care behaviors are essential for achieving blood sugar targets. This randomized, two-arm clinical trial will evaluate whether a structured narrative education program added to usual diabetes care improves glycemic control compared with usual care alone in adults with type 2 diabetes. Eligible participants (age ≥18 years) with suboptimal glycemic control (HbA1c ≥7.0% in the last 3 months) will be randomized 1:1 to either standard care or standard care plus narrative education. The narrative education program will be delivered by a family physician over 3 months and includes two individual face-to-face sessions (approximately 20-30 minutes) at Day 0 and Day 15 and four brief telephone reinforcement calls (approximately 3-5 minutes) on Days 30, 45, 60, and 75.
The primary outcome is the absolute change in HbA1c from baseline (Day 0) to Day 90. Secondary outcomes include changes in diabetes self-care activities (SDSCA-TR), diabetes-related distress (PAID-5-TR), and body mass index (BMI) from Day 0 to Day 90.
Eligibility
Primary outcome measure(s)
- Change in HbA1c (%) — Baseline (Day 0) to Day 90
Absolute change in glycated hemoglobin (HbA1c) from baseline (Day 0) to Day 90.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Ozerli Family Health Center No. 4 | Antakya | Hatay |
More Mustafa Kemal University trials in Turkey
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07307430 on ClinicalTrials.gov ↗ ← All trials in Turkey